Claire Hooper is the administrator of Adult Stem Cells Advocates and a contributor to Stem Cell Pioneers. She currently lives in Beaumont near Houston, TX. She was involved in a car accident more than two decades ago while she was working as a probation and parole officer which caused her knee and back injury and eventually led to her disability. As her knees and back began to rapidly deteriorate, she started doing extensive research on alternative treatments as opposed to the traditional ones which she felt were invasive, risky and could further lead to other surgeries and narcotic drug dependencies. She was quite optimistic that her own stem cells could treat her and improve her condition and is now seeking to receive her bone marrow derived stem cells to treat her orthopedic conditions. Find out more about her advocacy for stem cell treatments, how she fights for patient rights and urges everyone to sign up for the petition to eliminate the restriction on every patient’s rights to access their own stem cells.

Thank you for listening. We would appreciate your comments and reviews.

The Onwards Medical Breakthrough

Drug combination extends survival by more than a year in metastatic prostate cancer

“Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group.”

“The dramatic results in a multi-center phase III trial should change the way physicians have routinely treated such patients since the 1950s, they said.”

“This is the first study to identify a strategy that prolongs survival in newly diagnosed, metastatic prostate cancer,” said Christopher J. Sweeney, M.B.B.S, of Dana-Farber’s Lank Center for Genitourinary Oncology. He presented the results of the trial Sunday, June 1, 2014 at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.”